Colorectal cancer medical therapy: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-mgibson@perfuse.org +charlesmichaelgibson@gmail.com & -kfeeney@perfuse.org +kfeeney@elon.edu))
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Colon cancer}}
{{Colon cancer}}
'''Editor(s)-in-Chief:''' [[C. Michael Gibson]], M.S.,M.D. [mailto:charlesmichaelgibson@gmail.com]  Phone:617-632-7753; Elliot B. Tapper, M.D., Beth Israel Deaconess Medical Center
To view the medical therapy of familial adenomatous polyposis (FAP), click [[Familial adenomatous polyposis medical therapy|'''here''']]<br>
To view the medical therapy of hereditary nonpolyposis colorectal cancer (HNPCC), click [[Hereditary nonpolyposis colorectal cancer medical therapy|'''here''']]<br><br>
{{CMG}} {{AE}} Elliot B. Tapper, M.D., Saarah T. Alkhairy, M.D.
 


==Overview==
==Overview==
[[Chemotherapy]] is used to reduce the likelihood of metastasis developing, shrink tumor size, and slow tumor growth. Chemotherapy is often applied after surgery (adjuvant), before surgery (neo-adjuvant), or as the primary therapy if surgery is not indicated (palliative). Other therapies include radiation and support therapies.


==Medical Therapy==
==Medical Therapy==
===Chemotherapy===
===Chemotherapy===
[[Chemotherapy]] is used to reduce the likelihood of metastasis developing, shrink tumor size, or slow tumor growth. Chemotherapy is often applied after surgery (adjuvant), before surgery (neo-adjuvant), or as the primary therapy if surgery is not indicated (palliative).  The treatments listed here have been shown in [[clinical trial]]s to improve survival and/or reduce mortality rate and have been approved for use by the US Food and Drug Administration.
[[Chemotherapy]] is used to reduce the likelihood of metastasis developing, shrink tumor size, and slow tumor growth. Chemotherapy is often applied after surgery (adjuvant), before surgery (neo-adjuvant), or as the primary therapy if surgery is not indicated (palliative).  The treatments listed here have been shown in [[clinical trial]]s to improve survival and/or reduce mortality rate and have been approved for use by the US Food and Drug Administration.


*'''Adjuvant''' (after surgery) chemotherapy.  One regimen involves the combination of infusional [[5-fluorouracil]], [[leucovorin]], and [[oxaliplatin]] ([[FOLFOX]])
'''Adjuvant chemotherapy'''  
** [[5-fluorouracil]] (5-FU) or [[Capecitabine]] (Xeloda®)
One regimen involves the combination of infusional [[5-fluorouracil]], [[leucovorin]], and [[oxaliplatin]] ([[FOLFOX]])
** [[Leucovorin]] (LV, Folinic Acid)
*[[5-fluorouracil]] (5-FU) or [[Capecitabine]] (Xeloda®)
** [[Oxaliplatin]] (Eloxatin®)
*[[Leucovorin]] (LV, Folinic Acid)
*[[Oxaliplatin]] (Eloxatin®)


*Chemotherapy for '''metastatic''' disease. Commonly used first line [[chemotherapy regimen]]s involve the combination of infusional [[5-fluorouracil]], [[leucovorin]], and [[oxaliplatin]] ([[FOLFOX]]) with [[bevacizumab]] or infusional [[5-fluorouracil]], [[leucovorin]], and [[irinotecan]] ([[FOLFIRI]]) with [[bevacizumab]]
'''Chemotherapy for metastatic disease'''   
** [[5-fluorouracil]] (5-FU) or Capecitabine
Commonly used first line [[chemotherapy regimen]]s involve the combination of infusional [[5-fluorouracil]], [[leucovorin]], and [[oxaliplatin]] ([[FOLFOX]]) with [[bevacizumab]] OR infusional [[5-fluorouracil]], [[leucovorin]], and [[irinotecan]] ([[FOLFIRI]]) with [[bevacizumab]]
** [[Leucovorin]] (LV, Folinic Acid)
*[[5-fluorouracil]] (5-FU) or Capecitabine
** [[Irinotecan]] (Camptosar®)
*[[Leucovorin]] (LV, Folinic Acid)
** [[Oxaliplatin]] (Eloxatin®)
*[[Irinotecan]] (Camptosar®)
** [[Bevacizumab]] (Avastin®)
*[[Oxaliplatin]] (Eloxatin®)
** [[Cetuximab]] (Erbitux®)
*[[Bevacizumab]] (Avastin®)
** [[Panitumumab]] (Vectibix)
*[[Cetuximab]] (Erbitux®)
*[[Panitumumab]] (Vectibix)


*In clinical trials for treated/untreated metastatic disease. [http://saci.uthscsa.edu/ClinicalTrials/SelectedPhase1.html#PhINovel]
'''In clinical trials for treated/untreated metastatic disease''' [http://saci.uthscsa.edu/ClinicalTrials/SelectedPhase1.html#PhINovel]
** [[Bortezomib]] (Velcade®)
*[[Bortezomib]] (Velcade®)
** [[Oblimersen]] (Genasense®, G3139)
*[[Oblimersen]] (Genasense®, G3139)
** [[Gefitinib]] and [[Erlotinib]] (Tarceva®)
*[[Gefitinib]] and [[Erlotinib]] (Tarceva®)
** [[Topotecan]] (Hycamtin®)
*[[Topotecan]] (Hycamtin®)


===Radiation therapy===
===Radiation therapy===
Radiotherapy is not used routinely in colon cancer, as it could lead to [[radiation enteritis]], and it is difficult to target specific portions of the colon.  It is more common for radiation to be used in rectal cancer, since the rectum does not move as much as the colon and is thus easier to target.  Indications include:
Radiotherapy is not used routinely in colon cancer since it could lead to [[radiation enteritis]]. It is also difficult to target specific portions of the colon.  It is more commonly performed in rectal cancer since the rectum does not move as much as the colon and is easier to target.   
* Colon cancer
 
** Pain relief and palliation - targeted at [[metastasis|metastatic]] tumor deposits if they compress vital structures and/or cause pain
Indications include:
* Rectal cancer
*Colon cancer
** Neoadjuvant - given before surgery in patients with tumors that extend outside the rectum or have spread to regional lymph nodes, in order to decrease the risk of recurrence following surgery or to allow for less invasive surgical approaches (such as a low anterior resection instead of an abdomino-perineal resection)
:*Pain relief and palliation
** Adjuvant - where a tumor perforates the rectum or involves regional lymph nodes (AJCC T3 or T4 tumors or Duke's B or C tumors)
:*Targeted at [[metastasis|metastatic]] tumor deposits if they compress vital structures and/or cause pain
** Palliative - to decrease the tumor burden in order to relieve or prevent symptoms
*Rectal cancer
:*Neoadjuvant - given before surgery in patients with tumors that extend outside the rectum or have spread to regional lymph nodes in order to decrease the risk of recurrence following surgery or to allow for less invasive surgical approaches
:*Adjuvant - where a tumor perforates the rectum or involves regional lymph nodes (AJCC T3 or T4 tumors or Duke's B or C tumors)
:*Palliative - to decrease the tumor burden in order to relieve or prevent symptoms


Sometimes chemotherapy agents are used to increase the effectiveness of radiation by sensitizing tumor cells if present.
Sometimes chemotherapy agents are used to increase the effectiveness of radiation by sensitizing tumor cells if present.
===Immunotherapy===
[[Bacillus Calmette-Guérin]] (BCG) is being investigated as an adjuvant mixed with autologous tumor cells in immunotherapy for colorectal cancer.<ref>Mosolits S, Nilsson B, Mellstedt H. ''Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.'', Expert Rev. Vaccines, 2005;4:329-50. PMID 16026248.</ref>


===Support therapies===
===Support therapies===
Cancer diagnosis very often results in an enormous change in the patient's psychological wellbeing.  Various support resources are available from hospitals and other agencies which provide [[counseling]], social service support, [[cancer support group]]s, and other services.  These services help to mitigate some of the difficulties of integrating a patient's medical complications into other parts of their life.
Cancer diagnosis very often results in an enormous change in the patient's psychological wellbeing.  Various support resources are available from hospitals and other agencies which provide [[counseling]], social service support, [[cancer support group]]s, and other services.  These services help to mitigate some of the difficulties of integrating a patient's medical complications into other parts of their life.



Revision as of 14:03, 15 July 2015

Colorectal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Colorectal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Metastasis Treatment

Primary Prevention

Secondary Prevention

Follow-up

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Colorectal cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Colorectal cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Colorectal cancer medical therapy

CDC on Colorectal cancer medical therapy

Colorectal cancer medical therapy in the news

Blogs on Colorectal cancer medical therapy

Directions to Hospitals Treating Colorectal cancer

Risk calculators and risk factors for Colorectal cancer medical therapy

To view the medical therapy of familial adenomatous polyposis (FAP), click here
To view the medical therapy of hereditary nonpolyposis colorectal cancer (HNPCC), click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Elliot B. Tapper, M.D., Saarah T. Alkhairy, M.D.


Overview

Chemotherapy is used to reduce the likelihood of metastasis developing, shrink tumor size, and slow tumor growth. Chemotherapy is often applied after surgery (adjuvant), before surgery (neo-adjuvant), or as the primary therapy if surgery is not indicated (palliative). Other therapies include radiation and support therapies.

Medical Therapy

Chemotherapy

Chemotherapy is used to reduce the likelihood of metastasis developing, shrink tumor size, and slow tumor growth. Chemotherapy is often applied after surgery (adjuvant), before surgery (neo-adjuvant), or as the primary therapy if surgery is not indicated (palliative). The treatments listed here have been shown in clinical trials to improve survival and/or reduce mortality rate and have been approved for use by the US Food and Drug Administration.

Adjuvant chemotherapy One regimen involves the combination of infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)

Chemotherapy for metastatic disease Commonly used first line chemotherapy regimens involve the combination of infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) with bevacizumab OR infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab

In clinical trials for treated/untreated metastatic disease [2]

Radiation therapy

Radiotherapy is not used routinely in colon cancer since it could lead to radiation enteritis. It is also difficult to target specific portions of the colon. It is more commonly performed in rectal cancer since the rectum does not move as much as the colon and is easier to target.

Indications include:

  • Colon cancer
  • Pain relief and palliation
  • Targeted at metastatic tumor deposits if they compress vital structures and/or cause pain
  • Rectal cancer
  • Neoadjuvant - given before surgery in patients with tumors that extend outside the rectum or have spread to regional lymph nodes in order to decrease the risk of recurrence following surgery or to allow for less invasive surgical approaches
  • Adjuvant - where a tumor perforates the rectum or involves regional lymph nodes (AJCC T3 or T4 tumors or Duke's B or C tumors)
  • Palliative - to decrease the tumor burden in order to relieve or prevent symptoms

Sometimes chemotherapy agents are used to increase the effectiveness of radiation by sensitizing tumor cells if present.

Support therapies

Cancer diagnosis very often results in an enormous change in the patient's psychological wellbeing. Various support resources are available from hospitals and other agencies which provide counseling, social service support, cancer support groups, and other services. These services help to mitigate some of the difficulties of integrating a patient's medical complications into other parts of their life.

References


Template:WikiDoc Sources